Captopril-induced Changes in Prostaglandin Production
Open Access
- 1 June 1980
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 65 (6) , 1257-1264
- https://doi.org/10.1172/jci109788
Abstract
Captopril is a potent hypotensive agent whose efficacy has hitherto been attributed to its ability to alter either angiotensin II formation or kinin degradation. Our purpose was to examine captopril's acute effect on prostaglandin production, because changes in neither the renin-angiotensin nor the kallikrein-kinin systems appear adequate to account for the fall in arterial pressure. The plasma levels of angiotensin II, kinins, and prostaglandins were determined in response to increasing doses (5, 12.5, and 25 mg) of captopril and these responses were compared with the change in arterial pressure observed in nine supine normal male subjects studied on both a high (200 meq) and low (10 meq) sodium intake. Captopril significantly (P < 0.01) increased the levels of the 13,14-dihydro-15-keto metabolite of prostaglandin E2 (PGE2-M), a potent vasodilator, with similar responses being observed on both a high and a low sodium intake. No significant changes in the plasma levels of 6-keto-prostaglandin F 1α, or thromboxane B2, the stable products of prostacyclin and thromboxane A2, respectively, occurred. The depressor response to captopril correlated with the change in PGE2-M (r = 0.52, t = 5.44, P < 0.0001). On the other hand, although significant (P < 0.02) decrements in angiotensin II and increments in plasma kinins accompanied the hypotensive response in sodium-restricted subjects, in sodium-loaded subjects where the renin-angiotensin system was suppressed, no change in angiotensin II, and only a modest change in kinins was noted, even though significant (P < 0.01) decrements in diastolic blood pressure occurred (−10±2 mm Hg). Thus, changes in depressor prostaglandin production can better account for the hypotensive response to captopril, thereby extending to yet another vasoactive system an influence by this class of drugs and providing a new approach to dissecting the abnormality in the control of vascular tone in patients with hypertension.This publication has 25 references indexed in Scilit:
- The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man.Hypertension, 1979
- Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel WallsNew England Journal of Medicine, 1979
- Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.Hypertension, 1979
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Tumor promoting phorbol diesters stimulate release of radioactivity from [3H]-arachidonic acid labeled- but not [14C]linoleic acid labeled-cells. Indomethacin inhibits the stimulated release from [3H]arachidonate labeled cellsProstaglandins and Medicine, 1978
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture.Journal of Clinical Investigation, 1975
- Reciprocal Influence of Salt Intake on Adrenal Glomerulosa and Renal Vascular Responses to Angiotensin II in Normal ManJournal of Clinical Investigation, 1974
- Analysis of Prostaglandin F2a, and Metabolites in Blood during Constant Intravenous Infusion of Prostaglandin F2a, in the Human FemaleActa Physiologica Scandinavica, 1972